Gene therapy for effector cell regulation

Details Gene therapy for effector cell regulation Gene therapy for effector cell regulation

1995-12-29

1999-08-10

Stanton, Brian R.

Drug, bio-affecting and body treating compositions

Whole live micro-organism, cell, or virus containing

Genetically modified micro-organism, cell, or virus

514 44, 435 691, 4351723, 435375, A61K 4800, C12N 1563, C12N 1509

Patent

active

059355689

ABSTRACT:
The present invention provides a nucleic acid-based therapeutic composition to treat an animal with disease by controlling the activity of effector cells, including T cells, macrophages, monocytes and/or natural killer cells, in the animal. Therapeutic compositions of the present invention include superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules, depending upon the disease being treated. The present invention also relates to an adjuvant for use with nucleic acid-based vaccines. Adjuvant compositions of the present invention include an immunogen combined with superantigen-encoding nucleic acid molecules, either in the presence or absence of a cytokine-encoding nucleic acid molecule and/or chemokine-encoding nucleic acid molecules.

REFERENCES:
patent: 4994369 (1991-02-01), Krensky et al.
patent: 5145676 (1992-09-01), Fahey, III et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5593972 (1997-01-01), Weiner et al.
patent: 5641662 (1997-06-01), Debs et al.
Howard et al., "Chemokines: progress toward identifying molecular targets for therapeutic agents," TIBTECH, vol. 14, p. 7799-7804, Feb. 1996.
Taub et al., "Chemokines, inflammation and the immune system," Therapeutic Immunology, vol. 1, pp. 229-246, 1994.
Blackman et al., Life Sci., 57(19):1717-1735, 1995.
Donnelly et al., Ann. N.Y. Acad. Sci., 772:40-46, 1995.
Liu, Ann. N.Y. Acad. Sci., 772(DNA Vaccines):15-21, 1995.
Miethke et al., Int. Arch. Allergy Immunol., 106:3-7, 1995.
Miethke et al., Immunobiol., 189:270-284, 1993.
"Chemokines", pp. 79-85.
Bhardwaj et al., 1993, J. Exp. Med., 178:633-642.
Borremans et al., 1989, Infection and Immunity, 57(10):3123-3130.
Davatelis et al., 1988, J. Exp. Med., 167: 1939-1944.
Dohlsten et al., 1991, Proc. Natl. Acad. Sci. U.S.A., 88:9287-9291.
Hansson et al., 1992, Immunol. Lett., 34(3):229-236.
Hedlund et al., 1993, Cancer Immunol. Immunother., 36:89-93.
Hermann et al., 1993, Seminars in Immumol., 5:33-39.
Kalland et al., 1993, Med. Oncol. & Tumor Pharmacother., 10(1/2):37-47.
Lando et al., 1993, Cancer Immunol. Immunother., 36:223-228.
Lukacs et al., 1993, J. Exp. Med., 178:343-348.
Micusan et al., 1993, Seminars in Immunol., 5:3-11.
Newell et al., 1991, Proc. Natl. Acad. Sci. U.S.A., 88:1074-1078.
Ochi et al., 1993, J. Immunol., 151(6):3180-3186.
Rellahan et al., 1990, J. Exp. Med., 172:1091-1100.
Sherry et al., 1988, J. Exp. Med., 168:2251-2259.
White et al., 1989, Cell, 56:27-35.
Wiker et al., 1992, Microbiological Reviews, 56:648-661.

Affiliated with

Also associated with

Rating

Gene therapy for effector cell regulation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Gene therapy for effector cell regulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene therapy for effector cell regulation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1117535